NEW YORK (GenomeWeb) – Research enabled by GenomeDx’s Decipher GRID data-sharing network continues to yield data on both new and existing gene expression signatures with prognostic or predictive value for prostate cancer patients.
The most recent insight, discussed earlier this month in a study in JAMA Oncology, speaks to the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic four years ago.
In this case, using the company’s GRID database, researchers were able to apply a version of the existing PAM50 gene expression-based classifier — commercially developed by NanoString Technologies as the Prosigna test in breast cancer — to nearly 3,800 prostate cancer samples, showing for the first time that the signature also shows promise in classifying prostate cancer cases in ways that could predict response to post-operative androgen deprivation therapy.
However, the results also highlight how the unique model of the GRID program presents challenges to traditional diagnostic development models, and raises questions about the barriers between research and clinical medical practice.
Decipher GRID (which stands for Genomics Resource Information Database), is made possible by the fact that GenomeDx runs its clinical Decipher prognostic test using whole-genome microarrays. Though the company only reports